World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
84
Citations
23140
World Ranking
940
National Ranking
433

Medicine

D-Index
86
Citations
24040
World Ranking
14247
National Ranking
7205

Pablo Tebas publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Pablo Tebas sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 291 publications — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Pablo Tebas D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Pablo Tebas sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 84 D-Index — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Pablo Tebas is affiliated with the University of Pennsylvania in the United States. Their research focuses heavily on infectious diseases, immunology, and microbiology, with particular concentration in HIV research and treatment as well as COVID-19 clinical research studies.

The main fields of study for Tebas include Medicine and Immunology and Microbiology. Within these broad areas, their work spans several subfields such as Infectious Diseases, Virology, Immunology, Epidemiology, and Emergency Medicine.

Tebas's research topics cover a range of themes primarily related to HIV/AIDS and COVID-19, including:

  • HIV Research and Treatment
  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 Clinical Research Studies
  • Immune Cell Function and Interaction
  • HIV/AIDS Research and Interventions
  • HIV/AIDS drug development and treatment
  • HIV-related health complications and treatments

Frequent coauthors collaborating with Tebas include Luis J. Montaner, Karam Mounzer, Emmanouil Papasavvas, David B. Weiner, and Jay R. Kostman.

Tebas has published extensively in various scientific journals. The most common venues for their publications are:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Clinical Infectious Diseases
  • UNC Libraries
  • Open Forum Infectious Diseases
  • AIDS

Among their recent papers are:

  • "Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021" (2021, Nature Medicine)
  • "Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial" (2020, EClinicalMedicine)
  • "Single-cell multiomics reveals persistence of HIV-1 in expanded cytotoxic T cell clones" (2022, Immunity)
  • "Recommendations for measuring HIV reservoir size in cure-directed clinical trials" (2020, Nature Medicine)
  • "A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial" (2022, The Lancet. Gastroenterology & hepatology)

Best Publications

  • Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

    Pablo Tebas;David Stein;Winson W. Tang;Ian Frank

  • Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy.

    Pablo Tebas;William G. Powderly;Sherry Claxton;Donna Marin

  • Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

    Grace A. McComsey;Douglas Kitch;Eric S. Daar;Camlin Tierney

  • Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

    Susanna Naggie;Curtis Cooper;Michael Saag;Kimberly Workowski

  • Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

    Katharine J Bar;Michael C Sneller;Linda J Harrison;J Shawn Justement

  • Bone Disease in HIV Infection: A Practical Review and Recommendations for HIV Care Providers

    Grace A. McComsey;Pablo Tebas;Elizabeth Shane;Michael T. Yin

  • Prevalence and predictive value of intermittent viremia with combination hiv therapy.

    Diane V. Havlir;Roland Bassett;Diane Levitan;Peter Gilbert

  • Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

    Gerd Fätkenheuer;Mark Nelson;Adriano Lazzarin;Irina Konourina

  • Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

    Joel Gallant;Adriano Lazzarin;Anthony Mills;Chloe Orkin

  • Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

    Antonella Castagna;Franco Maggiolo;Giovanni Penco;David Wright

  • Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents

    Roger Bedimo;Naim M. Maalouf;Song Zhang;Henning Drechsler

  • Longitudinal Evolution of Bone Mineral Density and Bone Markers in Human Immunodeficiency Virus—Infected Individuals

    Kristin Mondy;Kevin Yarasheski;William G. Powderly;Michael Whyte

  • Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.

    Diane V. Havlir;Nick S. Hellmann;Christos J. Petropoulos;Jeannette M. Whitcomb

  • Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy

    Diane V. Havlir;Ian C. Marschner;Martin S. Hirsch;Ann C. Collier

  • Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021.

    Steven G. Deeks;Nancie Archin;Paula Cannon;Simon Collins

  • DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations

    Christian Hoffmann;Nana Minkah;Jeremy Leipzig;Gary Wang

  • HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D.

    Mario Cozzolino;Marcos Vidal;Maria Vittoria Arcidiacono;Pablo Tebas

  • Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report.

    Pablo Tebas;Christine C. Roberts;Kar Muthumani;Emma L. Reuschel

  • A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia.

    Valerianna Amorosa;Marie Synnestvedt;Robert Gross;Harvey Friedman

  • Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.

    Pablo Tebas;Shu Ping Yang;Jean D. Boyer;Emma L. Reuschel

  • Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides.

    Michael P Dubé;Robert A Parker;Pablo Tebas;Steven K Grinspoon

Frequent Co-Authors

William G. Powderly
William G. Powderly Washington University in St. Louis
Luis J. Montaner
Luis J. Montaner The Wistar Institute
Ian Frank
Ian Frank University of Pennsylvania
Grace A. McComsey
Grace A. McComsey Case Western Reserve University
Ann C. Collier
Ann C. Collier University of Washington
Jean D. Boyer
Jean D. Boyer Inovio Pharmaceuticals (United States)
Kevin E. Yarasheski
Kevin E. Yarasheski Washington University in St. Louis
David B. Weiner
David B. Weiner The Wistar Institute
Douglas D. Richman
Douglas D. Richman University of California, San Diego
Jeffrey M. Jacobson
Jeffrey M. Jacobson Drexel University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in microbiology, exploring related online degrees can open up diverse career pathways. Many find that advanced degrees, like a Master of Public Health (MPH), complement their microbiology background well. If you’re looking for options with accessible admissions, consider researching the fastest and easiest online mph programs. These programs can provide a quicker route to expanding your expertise in public health and epidemiology.

Career-wise, roles such as a Child Life Specialist offer meaningful work supporting the wellbeing of children in healthcare settings. Understanding how much does a child life specialist make helps gauge the financial potential of this path. This role often requires additional education and certification, but is a rewarding option for those passionate about healthcare and child development.

Online education options also extend opportunities to a diverse range of students. For example, those with criminal records can find guidance on what can a felon go to college for. This resource highlights accessible degree programs that can lead to stable and fulfilling careers, emphasizing second chances in higher education.

Additionally, the healthcare field continues to evolve with innovative roles like the Functional Medicine Nurse Practitioner. Programs designed to train in this specialty can be explored through functional medicine nurse practitioner programs, offering microbiology graduates a path into holistic patient care and advanced nursing practice.

Best Scientists Citing Pablo Tebas

Trending Scientists

Recently Published Articles